Baricitinib - Eli Lilly and Company/Incyte Corporation
Alternative Names: INCB 028050; INCB 28050; LY 3009104; OlumiantLatest Information Update: 04 Oct 2024
Price :
$50 *
At a glance
- Originator Incyte Corporation
- Developer Eli Lilly; Eli Lilly and Company; Incyte Corporation; Natco Pharma
- Class Acetonitriles; Anti-inflammatories; Antipsoriatics; Antirheumatics; Azetidines; Eye disorder therapies; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alopecia areata; Atopic dermatitis; Rheumatoid arthritis
- Registered COVID 2019 infections
- Phase III Juvenile rheumatoid arthritis; Uveitis
- Phase II/III Aicardi-Goutieres syndrome; Hereditary autoinflammatory diseases
- Discontinued Diabetic nephropathies; Primary biliary cirrhosis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus
Most Recent Events
- 04 Oct 2024 Discontinued - Phase-II for Primary biliary cirrhosis in Puerto Rico, United Kingdom, USA (PO) prior to October 2024 (Eli Lilly and Company pipeline, October 2024)
- 04 Sep 2024 Eli Lilly and company and Eva Pharma agree to co-promote baricitinib in Africa
- 23 Jul 2024 Adverse events data from a phase III trial in Uveitis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)